Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Conditions
Brief summary
This clinical trial explores if using virtual reality (VR) headsets will help to improve patient understanding of their disease and decrease anxiety about treatment. Three-dimensional (3D) images may help the patient visualize their tumor and location better and therefore understand potential side effects. Visualizing a virtual representation of the magnetic resonance imaging (MRI) linear accelerator (Linac) may decrease treatment related anxiety.
Detailed description
PRIMARY OBJECTIVE: I. Examine patient reported comprehension of their tumor characteristics and treatment plan following 3D virtual reality review of their imaging. SECONDARY OBJECTIVE: I. Examine patient reported treatment related anxiety prior to and following virtual reality (VR) simulation of the MRI Linac treatment process. OUTLINE: Patients are assigned to 1 of 2 cohorts. COHORT I: Patients receive two-dimensional (2D) image review using standard computer screen on study. Patients undergo MRI and computed tomography (CT) imaging at screening and on study. COHORT II: Patients receive image review using virtual reality stimulation on study. Patients also view MRI treatment room using virtual reality stimulation. Patients undergo MRI and CT imaging at screening and on study.
Interventions
PROCEDUREMagnetic Resonance Imaging
Undergo MRI
PROCEDUREComputed Tomography
Undergo CT
OTHERBest Practice
Review imaging on standard computer screen
OTHERQuestionnaire Administration
Complete questionnaire
Review virtual reality images
Sponsors
Thomas Jefferson University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age: above 18 years * Participants must be histologically proven neoplasm * Planned to undergo radiation treatment using the MR Linac
Exclusion criteria
* Inability to tolerate virtual reality headset * Non-English speaking patients * Pediatric patients are ineligible
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Increase in composite knowledge questionnaire score | At Baseline | Pre- and post-intervention knowledge summary scores and anxiety scores will be summarized using means, standard deviations, and ranges. Average change will be estimated for each group along with 95% confidence intervals and the difference between groups will be estimated with a 95% confidence interval. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| General anxiety | At Baseline | Pre-intervention knowledge summary scores and anxiety scores will be summarized using means, standard deviations, and ranges. Average change will be estimated for each group along with 95% confidence intervals and the difference between groups will be estimated with a 95% confidence interval. |
| MRI specific anxiety | Baseline and after MRI scan at time of planning scan | Pre- and post-intervention knowledge summary scores and anxiety scores will be summarized using means, standard deviations, and ranges. Average change will be estimated for each group along with 95% confidence intervals and the difference between groups will be estimated with a 95% confidence interval. |
| Plan review understanding | Baseline and at first on treatment visit (after starting radiation) | Pre- and post-intervention knowledge summary scores and anxiety scores will be summarized using means, standard deviations, and ranges. Average change will be estimated for each group along with 95% confidence intervals and the difference between groups will be estimated with a 95% confidence interval. |
Countries
United States
Outcome results
None listed